Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Net Income (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Net Income for 13 consecutive years, with $8.7 million as the latest value for Q4 2025.

  • Quarterly Net Income rose 289.09% to $8.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $351.1 million through Dec 2025, up 43.28% year-over-year, with the annual reading at $351.1 million for FY2025, 43.97% up from the prior year.
  • Net Income hit $8.7 million in Q4 2025 for Coherus Oncology, down from $9.0 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $342.6 million in Q2 2025 to a low of -$172.9 million in Q1 2021.
  • Historically, Net Income has averaged -$11.0 million across 5 years, with a median of -$39.1 million in 2021.
  • Biggest five-year swings in Net Income: tumbled 700.7% in 2021 and later soared 717.15% in 2025.
  • Year by year, Net Income stood at -$45.7 million in 2021, then decreased by 28.85% to -$58.9 million in 2022, then plummeted by 35.32% to -$79.7 million in 2023, then soared by 94.22% to -$4.6 million in 2024, then soared by 289.09% to $8.7 million in 2025.
  • Business Quant data shows Net Income for CHRS at $8.7 million in Q4 2025, $9.0 million in Q3 2025, and $342.6 million in Q2 2025.